A retrospective analysis of anti-osteoporosis medication trends among patients under 50 years old in nine major regions of China from 2016 to 2019.

• DOI: 10.7717/peerj.19187
• Publication Date: 2025-01-01
• Authors: Bo Chen; Liying Chen; Zhenwei Yu; Yanting Sun; Liucheng Li; Wang Chen; Siqi Wang; Yan Hu; Lian‐Di Kan; Liucheng Li

This study aimed to assess the national trends in osteoporosis prescriptions among Chinese adult outpatients aged less than 50 years with osteoporosis, from 2016 2019. Prescriptions for hospitals nine major areas were extracted database of Hospitals Prescription Analysis Cooperative Project. Trends annual and expenditure analyzed. The number hospital visits showed an increasing trend year by 18,412 23,447 2019 (P = 0.029), corresponding cost increased 2,083,872.94 yuan (CNY) 2,643,508.59 CNY 0.032). result that share newer osteoporotic use medicines continuously, accounting 34.3% 26.8% expenditures found under age, medicine year. However, bone resorption inhibitors formation promoters this group did not change significantly, only small proportion. development prescription reflected current situation research China. Meanwhile, study, we also investigated epidemiology China patients whom incidence trend, which reminded us accelerate prevention osteoporosis.